Elanco Animal Health Incorporated (NYSE:ELAN) Shares Sold by TD Asset Management Inc

TD Asset Management Inc trimmed its stake in Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 30.5% during the first quarter, according to its most recent 13F filing with the SEC. The firm owned 143,393 shares of the company's stock after selling 62,942 shares during the period. TD Asset Management Inc's holdings in Elanco Animal Health were worth $1,506,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently made changes to their positions in ELAN. American Century Companies Inc. grew its stake in shares of Elanco Animal Health by 1.8% during the fourth quarter. American Century Companies Inc. now owns 128,264 shares of the company's stock worth $1,553,000 after purchasing an additional 2,280 shares in the last quarter. LPL Financial LLC raised its holdings in Elanco Animal Health by 15.9% during the fourth quarter. LPL Financial LLC now owns 161,183 shares of the company's stock worth $1,952,000 after purchasing an additional 22,163 shares in the last quarter. Orion Portfolio Solutions LLC boosted its holdings in shares of Elanco Animal Health by 14.3% in the 4th quarter. Orion Portfolio Solutions LLC now owns 33,396 shares of the company's stock valued at $404,000 after buying an additional 4,169 shares in the last quarter. Geode Capital Management LLC grew its position in shares of Elanco Animal Health by 4.0% in the 4th quarter. Geode Capital Management LLC now owns 8,180,840 shares of the company's stock valued at $99,102,000 after buying an additional 312,165 shares during the last quarter. Finally, Trexquant Investment LP boosted its stake in Elanco Animal Health by 85.5% in the fourth quarter. Trexquant Investment LP now owns 343,883 shares of the company's stock valued at $4,164,000 after acquiring an additional 158,520 shares in the last quarter. Hedge funds and other institutional investors own 97.48% of the company's stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the company. Leerink Partners raised Elanco Animal Health from a "market perform" rating to an "outperform" rating and set a $18.00 price objective for the company in a report on Thursday, July 17th. William Blair upgraded shares of Elanco Animal Health from a "market perform" rating to an "outperform" rating in a research note on Thursday, June 26th. Wall Street Zen raised Elanco Animal Health from a "hold" rating to a "buy" rating in a research report on Saturday, July 5th. Leerink Partnrs raised shares of Elanco Animal Health from a "hold" rating to a "strong-buy" rating in a report on Thursday, July 17th. Finally, Stifel Nicolaus lifted their price objective on Elanco Animal Health from $16.00 to $17.00 and gave the company a "buy" rating in a report on Wednesday, July 2nd. Two investment analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $16.17.

Elanco Animal Health Stock Up 16.4%

Shares of ELAN stock traded up $2.29 during trading hours on Thursday, hitting $16.24. 9,106,985 shares of the company were exchanged, compared to its average volume of 5,370,871. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.46 and a current ratio of 2.71. The stock has a market capitalization of $8.06 billion, a price-to-earnings ratio of 21.84, a P/E/G ratio of 2.76 and a beta of 1.66. Elanco Animal Health Incorporated has a one year low of $8.02 and a one year high of $16.70. The business's 50-day simple moving average is $14.20 and its two-hundred day simple moving average is $12.02.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The company reported $0.26 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.20 by $0.06. Elanco Animal Health had a return on equity of 7.54% and a net margin of 8.43%. Elanco Animal Health's revenue for the quarter was up 4.8% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.30 EPS. Sell-side analysts predict that Elanco Animal Health Incorporated will post 0.91 EPS for the current fiscal year.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.